Promoted Content Promoted Content

X

Find Novel Drugs for Infections and Infectious Diseases under Development in CHINA

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Proxalutamide,Ivermectin,Azithromycin

            Therapeutic Area: Infections and Infectious Diseases Product Name: GT0918

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 29, 2020

            Details:

            Clinical trial of anti-androgen treatment Proxalutamide (GT0918) for the novel coronavirus disease (COVID-19) has reached the initial target of 381 patients enrolment on 25 October 2020. Also, it has demonstrated a positive trend.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Proxalutamide

            Therapeutic Area: Infections and Infectious Diseases Product Name: GT0918

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Applied Biology

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration July 14, 2020

            Details:

            The clinical study is a randomized controlled study of an anti-androgen (5-alpha reductase inhibitor) as a treatment for mildly symptomatic COVID-19 patients. The companies have teamed but to evaluate efficacy and safety of Proxalutamide.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): COVID-19 neutralizing antibody

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Institut Pasteur Shanghai

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership June 10, 2020

            Details:

            According to the agreement, Alphamab Oncology and Institut Pasteur Shanghai will form a joint project team. Alphamab Oncology is responsible for providing its proprietary Mixed Antibodies Platform, constructing humanized antibodies and recombinant engineered cell lines,